Rich People Trades
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Rich People Trades

Investing

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

by admin September 16, 2025
September 16, 2025
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) (‘Lobe Sciences’ or the ‘Company’) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company’s recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

Alongside the schedule of pre-booked meetings matching investors with appropriate projects, the conference program will provide amble opportunities to mix and mingle with the industry professionals and catch up on key industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register to request for a free invitation here.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in Toronto and New York. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About lobe sciences ltd.

Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:

  • Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.

Lobe’s pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.

For additional Information, please contact:

lobe sciences ltd.
info@lobesciences.com
www.lobesciences.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265683

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

previous post
Alice Queen raises $1M via issue of Convertible Notes
next post
Robotics Stocks: 10 Biggest Companies in 2025

Related Posts

Empire Metals Limited to Present at the Metals...

May 3, 2025

Drill Contract Awarded for Elizabeth Hill. Technical Visit...

May 9, 2025

CHARBONE Hydrogen Provides Update on Grid Interconnection with...

March 7, 2025

Red Metal Resources Commences Sampling and Mapping Program...

March 13, 2025

Carbonxt Group

July 25, 2025

Halcones Precious Metals Announces AGM Results

July 18, 2025

Pre-Feasibility Study Launched for 10,000pta WA Facility

August 19, 2025

Oil and Gas Price Update: Q1 2025 in...

April 24, 2025

Bold Ventures

June 14, 2025

Crypto Market Update: Markets Pull Back After Fed...

August 2, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      First lady Melania Trump’s new official portrait revealed

      January 28, 2025
    • 2

      American fighters are dying in Ukraine in growing numbers. Bringing their bodies home is a complex task

      January 30, 2025
    • 3

      ECOWAS pledges to ‘keep door open’ after 3 coup-hit West African nations exit regional bloc

      January 30, 2025
    • 4

      Vale Launches Strategic Review of Thompson Nickel Operations Amid Market Challenges

      January 28, 2025
    • 5

      Europe’s busiest airport is set to get bigger, as Britain green-lights tortured Heathrow expansion project

      January 30, 2025
    • 6

      Top Altcoins to Watch in 2025: An Investor’s Guide

      January 28, 2025
    • 7

      DeepSeek is giving the world a window into Chinese censorship and information control

      January 30, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: richpeopletrades.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 richpeopletrades.com | All Rights Reserved